Case | Paper | Cancer | Sample | Drug | Response | Mutation | Mutation_type |
1 | Synder | Melanoma | CR4880 | Ipilimumab | Responder | p.Y3858_splice | Missense |
2 | Synder | Melanoma | PR4092 | Ipilimumab | Responder | p.R3216K | Missense |
3 | Rizvi | NSCLC | DI6359 | Pembrolizumab | Responder | p.V1844L | Missense |
4 | Rizvi | NSCLC | DM123062 | Pembrolizumab | Non-responder | p.R2430* | Nonsense |
5 | Rizvi | NSCLC | HE3202 | Pembrolizumab | Responder | p.D3020H | Missense |
6 | Van Allen | Melanoma | Pat110 | Ipilimumab | Non-responder | p.S3876N | Missense |
7 | Van Allen | Melanoma | Pat117 | Ipilimumab | Responder | p.R2538W | Missense |
8 | Van Allen | Melanoma | Pat132 | Ipilimumab | Responder | p.W4037* | Nonsense |
9 | Van Allen | Melanoma | Pat138 | Ipilimumab | Responder | p.P1159L;p.P1159S | Missense; missense |
10 | Van Allen | Melanoma | Pat28 | Ipilimumab | non-responder | p.R2253_splice | Splice_site |
11 | Van Allen | Melanoma | Pat32 | Ipilimumab | Non-responder | p.S104F | Missense |
12 | VanAllen | Melanoma | Pat38 | Ipilimumab | Responder | p.V3297M | Missense |
13 | VanAllen | Melanoma | Pat62 | Ipilimumab | Non-responder | p.E1580fs | Frameshift |
14 | VanAllen | Melanoma | Pat70 | Ipilimumab | Non-responder | p.H2390Y | Missense |
15 | Anagnostou | NSCLC | CGLU161T1 | Anti-PD-1, anti-CTLA4 | Responder | p.T2176A | Missense |
16 | Riaz | Melanoma | Pt60 | Ipilimumab | Non-responder | p.G2517* | Stop_gained&splice_region_variant |
17 | Riaz | Melanoma | Pt65 | Ipilimumab | Responder | p.A2302V | Missense_variant |
18 | Miao | RCC | RCC_68 | Nivolumab | Non-responder | p.T2602I | Missense_variant |
19 | Miao | RCC | RCC_117 | Nivolumab | Responder | p.Y3114F | Missense_variant |
Rizvi et al,8 Van Allen et al,23 Anagnostou et al,26 Miao et al,24 Snyder et al,22 Riaz et al.25
NSCLC, non-small-cell lung carcinoma; PD-1, programmed cell death protein 1 pathway; PRKDC, protein kinase, DNA-activated, catalytic polypeptide; RCC, renal cell carcinoma.